Padcev 30 mg Price
Pronunciation: PAD-sev
Generic name: Enfortumab vedotin
Dosage form: Injection for Intravenous infusion
Drug class: Miscellaneous Antineoplastics

What is Padcev?

Padcev (Enfortumab vedotin) is an antibody-drug conjugate that is given as an intravenous infusion by a healthcare provider and may be used to treat adults with urothelial cancer, the most common type of bladder cancer that is locally advanced or has spread (metastasized) either:

• In combination with pembrolizumab (Keytruda)
• As a single agent in patients who have previously received an immunotherapy medicine and chemotherapy that contains platinum, OR who are not able to receive chemotherapy that contains the medicine cisplatin and have already received 1 or more prior lines of standard bladder cancer therapy.

Padcev is a conjugate medicine that contains two active parts: a human IgG1 kappa directed against Nectin-4 which is a protein located on the surface of cells and highly expressed in bladder cancer and MMAE (monomethyl auristatin E), which is a microtubule-disrupting agent that has been attached to the antibody via a protease-cleavable linker. After Padcev attaches to the surface of cancer cells expressing Nectin-4, it then enters the cells releasing MMAE. This causes the cells to stop dividing and programmed cell death (apoptosis), affecting the growth of the cancer.

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.

•PADCEV may be used with pembrolizumab (also known as Keytruda®), or

•PADCEV may be used alone if you:

–Have received an immunotherapy medicine and chemotherapy that contains platinum, or

–Are not able to receive a chemotherapy that contains

How is Padcev given?

Padcev is injected into a vein by a healthcare provider.

• This medicine must give slowly over 30 minutes.
• Tell your medical caregivers if you feel any burning or pain when Padcev is inject.

Padcev is give over periods called “cycles”.

• If you receive Padcev alone, each treatment cycle is 28 days. You will receive Padcev on days 1, 8, and 15 of every treatment cycle. Your doctor will determine how many cycles you need.
• If you receive Padcev in combination with pembrolizumab (Keytruda), each treatment cycle is 21 days. You will receive Padcev on days 1 and 8 of every cycle. Your doctor will determine how many cycles you need.

What are the side effects of Padcev?

Get emergency medical help if you have signs of an allergic reaction to Padcev such as hives; difficulty breathing; or swelling of your face, lips, tongue, or throat.

This medicine can cause a severe or life-threatening skin rash. Get emergency medical help if you have a worsening rash with itching, blistering, peeling, skin lesions that look like rings, fever or flu-like symptoms, swollen glands, or painful sores in your mouth, nose, throat, or genital area.

Padcev can cause high blood sugar (hyperglycemia) even if you have never had it before or if you are not diabetic. Severe hyperglycemia may be life-threatening. Your blood sugar may need to be checked often. Call your doctor at once if you have symptoms of high blood sugar, such as:

• Increased thirst, dry mouth, fruity breath odor
• Increased urination
• Blurred vision, confusion, drowsiness or
• Nausea, vomiting, stomach pain, loss of appetite.

What other drugs will affect Padcev?

Many drugs can interact with Padcev 30 mg, which may increase the risk of side effects. Tell your doctor about all your other medicines, including prescription and over-the-counter medicines, vitamins, and herbal products.

Use of Padcev 30 mg together with dual P-gp and strong CYP3A4 inhibitors (such as Ketoconazole, Itraconazole, ritonavir, or Clarithromycin) may increase the exposure to MMAE.

Storage

Store unopened Padcev vials in the refrigerator at 2ºC to 8ºC (36ºF to 46ºF) in the original carton. Do not freeze. Do not shake.

Once reconstituted add Padcev 30 mg to the infusion bag immediately. Reconstituted vials may be stored for up to 24 hours in refrigeration at 2°C to 8°C (36°F to 46°F). DO NOT FREEZE. Discard unused vials with a reconstituted solution beyond the recommended storage time.

Padcev is a hazardous drug. enfortumab vedotin 30 mg Follow all relevant special handling and disposal procedures.

Ingredients

Active: Enfortumab vedotin-ejfv

Inactive: Histidine, Histidine Hydrochloride Monohydrate, Polysorbate 20, and Trehalose Dihydrate.

Supplied as 20 mg and 30 mg single-dose vials.

Contains no preservatives.

Before taking.

Before receiving Padcev 30 mg, tell your Healthcare provider about all of your medical conditions, including if you:

• Are currently experiencing numbness or tingling in your hands or Feet
• Have a history of high blood sugar or Diabetes.
• Have liver Problems.
• Are pregnant or plan to become Pregnant.
• Are breastfeeding or plan to breastfeed.

Pregnancy

Padcev 30 mg can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment.

If you are a female who can become pregnant your healthcare provider should do a pregnancy test before you start treatment with Padcev and you should use an effective method of birth control during your treatment and for at least 2 months after the last dose. Padcev may affect your chances of having children in the future.

Males with a female sexual partner who can become pregnant should use an effective method of birth control during treatment and for at least 4 months after the last dose of Padcev. It may be harder for you to get a woman pregnant while you are using this medicine, but you should still use birth control to prevent pregnancy because the medicine can harm an unborn baby. If your female partner is already pregnant, Padcev 30 mg Price can harm the unborn baby, and sexual intercourse is not recommended. Tell your doctor right away if a pregnancy occurs.

Breastfeeding

It is not known if Padcev passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after the last dose of Padcev.

Warnings

Padcev 30 mg enfortumab vedotin can cause a severe or life-threatening skin rash including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Get emergency medical help if you have a worsening rash with itching, blistering, peeling, skin lesions that look like rings, fever or flu-like symptoms, swollen glands, or painful sores in your mouth, nose, throat, or genital area.

Padcev can cause high blood sugar (hyperglycemia) even if you have never had it before or if you are not diabetic. Severe hyperglycemia may be life-threatening. Your blood sugar may need to be checked often. Padcev should withal if blood glucose rises above is >250 mg/dL.

Severe and life-threatening fatal pneumonitis/interstitial lung disease (ILD) and peripheral neuropathy have been reported with Padcev enfortumab vedotin . Your healthcare provider will monitor you for these.

Padcev can also cause dry eyes, vision changes, enfortumab vedotin 30 mg and other eye disorders. Your doctor will monitor you for these with periodic eye examinations and may tell you to use artificial-tear eye drops to help prevent dry eyes and other eye drops.

Infusion site reactions may also occur.

Padcev can cause fetal harm. Women of childbearing age and men with partners who could become pregnant should use effective contraception.

It is not know if this medicine is safe and effective in children.

What is the most important information I should know about PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions.

Firstly Skin reactions including severe skin reactions have happened in people treated with Padcev 30 mg Price and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with Padcev 30 mg Price completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

• Target lesions (skin reactions that look like rings)
• Rash or itching that continues to get worse.
• Blistering or peeling of the skin
• Painful sores or ulcers in mouth or nose, throat, or genital area
• Fever or flu-like symptoms
• Swollen lymph nodes
• See “What are the possible side effects of PADCEV?” for more information about side effects.

FAQ

What is Padcev used for?

249 / 5000 10,000 Characters ♛ On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin (Padcev) in combination with pembrolizumab (Keytruda) for people with colon cancer that has spread to other parts of the body or cannot be removed.

How long is enfortumab infusion?

The recommended dose of enfortumab vedotin is 1.25 mg/kg (up to 125 mg for patients ≥100 kg) given as an intravenous infusion over 30 minutes on days 1, 8 and 15 of treatment. 28 days until the disease progresses. or unacceptable toxicity.

What is the warning for Padcev?

PADCEV can cause serious and fatal adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which occur early in the course of treatment but may occur later. Monitor patients carefully for skin reactions.

Is PADCEV a chemo?

Is PADCEV chemotherapy or immunotherapy? PADCEV works differently from chemotherapy or immunotherapy you may have had before, because PADCEV is an antibody drug conjugate (ADC). PADCEV works by delivering the drug directly to certain cancer cells, but it can also damage normal cells and cause side effects.

How quickly does PADCEV work?

What is the most important information I should know about PADCEV?

High blood sugar (hyperglycemia)

An increase in blood sugar is common during treatment with Padcev 30 mg Price. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV enfortumab vedotin Price. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including frequent urination, increased thirst, blurred vision, Enfortumab Vedotin Price confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Lung problems. 

PADCEV enfortumab vedotin Price may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV enfortumab vedotin Price is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.

Nerve problems. 

Secondly Nerve problems, called peripheral neuropathy, are common during treatment with PADCEV enfortumab vedotin and can sometimes be severe. Because Nerve problems may happen more often when Padcev 30 mg Price is given in combination with enfortumab vedotin Price pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.

Eye problems.

Thirdly Certain eye problems are common during treatment with Padcev 30 mg Price. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.

Leakage of Padcev 30 mg Price enfortumab vedotin out of your vein into the tissues around your infusion site (extravasation). If PADCEV enfortumab vedotin Price leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.

More Info

Padcev, known by its pronunciation, is a breakthrough in cancer treatment, offering hope with its formulation Padcev 30 mg. The Padcev price in India reflects its value in the healthcare market, bringing the advanced therapy of enfortumab vedotin closer to patients in need. While Padcev 30mg stands out for its efficacy, the treatment landscape also includes pembrolizumab, another cancer therapy with noted pembrolizumab price in India.

The cost of enfortumab vedotin in India and pembrolizumab in India is a significant consideration for patients seeking these treatments. Padcev injection represents a significant advancement in the treatment options available, demonstrating the importance of accessibility to such pioneering therapies. The entry of Padcev 20 mg and its pricing strategy are crucial for expanding patient access to effective cancer care. With Padcev’s introduction into the market, it joins the ranks of innovative treatments changing the landscape of cancer therapy.